PSP Weight Loss and Cachexia

PSP Weight Loss and Cachexia

Weight loss and cachexia represent significant non-motor manifestations in Progressive Supranuclear Palsy (PSP), contributing to disease progression, quality of life decline, and increased mortality risk. Unlike simple malnutrition, cachexia in PSP involves a complex metabolic syndrome characterized by ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support[@litvan1996].

Epidemiology

Weight loss occurs in the majority of PSP patients and often begins early in the disease course:

• Prevalence: 50-75% of PSP patients experience clinically significant weight loss (>5% body weight)[@dellipizzi2022]
• Onset: Often begins within the first 2-3 years of symptom onset
• Progression: Weight loss typically accelerates as disease advances
• Severity: Up to 15-25% of body weight may be lost prior to death

Compared to Parkinson's disease (PD), PSP patients tend to experience more severe and earlier weight loss, with a median weight loss of 8-12% of baseline body weight over the disease course[@muELLER2017].

Pathophysiology

Multifactorial Mechanisms

The weight loss and cachexia in PSP result from multiple overlapping mechanisms:

...

PSP Weight Loss and Cachexia

Weight loss and cachexia represent significant non-motor manifestations in Progressive Supranuclear Palsy (PSP), contributing to disease progression, quality of life decline, and increased mortality risk. Unlike simple malnutrition, cachexia in PSP involves a complex metabolic syndrome characterized by ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support[@litvan1996].

Epidemiology

Weight loss occurs in the majority of PSP patients and often begins early in the disease course:

• Prevalence: 50-75% of PSP patients experience clinically significant weight loss (>5% body weight)[@dellipizzi2022]
• Onset: Often begins within the first 2-3 years of symptom onset
• Progression: Weight loss typically accelerates as disease advances
• Severity: Up to 15-25% of body weight may be lost prior to death

Compared to Parkinson's disease (PD), PSP patients tend to experience more severe and earlier weight loss, with a median weight loss of 8-12% of baseline body weight over the disease course[@muELLER2017].

Pathophysiology

Multifactorial Mechanisms

The weight loss and cachexia in PSP result from multiple overlapping mechanisms:

1. Dysphagia and swallowing dysfunction

• Progressive dysphagia affects 65-90% of PSP patients
• Oral phase dysfunction: tongue weakness, delayed oral transit
• Pharyngeal phase dysfunction: delayed pharyngeal clearance
• Reduced caloric intake due to eating avoidance due to fear of choking
• See also: [PSP Speech and Swallowing Disorders](/mechanisms/psp-speech-swallowing-disorders)

2. Olfactory dysfunction

• Hyposmia/anosmia present in 70-85% of PSP patients
• Reduces appetite through diminished smell of food
• Contributes to anorexia
• See also: [PSP Olfactory Dysfunction](/mechanisms/psp-olfactory-dysfunction)

3. Depression and apathy

• Major depression: 15-40% prevalence
• Apathy: 40-60% prevalence
• Loss of interest in eating
• See also: [PSP Neuropsychiatric Symptoms](/diseases/psp-neuropsychiatric-symptoms)

4. Cognitive impairment

• Frontal executive dysfunction affecting meal planning and preparation
• Agnosia for food items
• Loss of independent eating abilities
• See also: [PSP Cognitive Impairment](/diseases/psp-cognitive-impairment)

5. Metabolic alterations

• Elevated resting energy expenditure
• Dysregulated lipid metabolism
• Mitochondrial dysfunction affecting cellular energy production
• See also: [PSP Mitochondrial Dysfunction](/mechanisms/psp-mitochondrial-dysfunction)

6. Neuroinflammation

• Chronic neuroinflammatory state increases catabolism
• Elevated cytokines (IL-6, TNF-alpha) promote muscle wasting

7. Autonomic dysfunction

• Gastroparesis and reduced gastric motility
• Thermoregulatory dysfunction affecting metabolic rate
• See also: [PSP Autonomic Dysfunction](/mechanisms/psp-autonomic-dysfunction)

Clinical Implications

Mortality Risk

Weight loss and cachexia significantly impact survival:

• Prognostic factor: Weight loss >10% body weight is an independent predictor of mortality[@cicolin2023]
• Hazard ratio: 1.5-2.0x increased mortality risk with significant weight loss[@orimo2008]
• Cause: Contributing to frailty, falls, immunosuppression
• Leading cause of death: [Aspiration pneumonia](/mechanisms/psp-mortality-survival) - often secondary to dysphagia and weakness

Disease Progression

Weight loss correlates with:

• Faster clinical deterioration
• Reduced response to therapeutic interventions
• Decreased functional reserve
• Increased falls due to weakness

Quality of Life

Impact on quality of life includes:

• Reduced independence in activities of daily living
• Decreased socialization around meals
• Body image concerns
• Fatigue and weakness
• See also: [PSP Quality of Life and Caregiver](/diseases/psp-quality-of-life-caregiver)

Assessment

Clinical Measures

• Monthly weight monitoring: Track weight changes
• BMI calculation: less than 18.5 kg/m2 indicates underweight
• Mini Nutritional Assessment (MNA): Validated screening tool
• Dynamometry: Handgrip strength as proxy for muscle mass

Biomarkers

• Serum albumin: Nutritional marker (often low in cachexia)
• Prealbumin (transthyretin): More sensitive to acute changes
• Cholesterol: Low levels associated with poor prognosis
• IL-6, TNF-alpha: Inflammatory markers correlate with catabolism

Management Approaches

Nutritional Interventions

1. Caloric supplementation

• High-calorie oral supplements (e.g., Ensure, Boost)
• Between-meal snacks
• Calorie-dense foods

2. Texture modification

• Pureed diets as needed
• Thickened liquids for dysphagia
• See also: [PSP Rehabilitation Approaches](/mechanisms/psp-rehabilitation-approaches)

3. Feeding assistance

• Caregiver-assisted feeding
• Adaptive equipment
• Supervised mealtimes

Pharmacological Approaches

• Appetite stimulants: Megestrol acetate, dronabinol (limited evidence)
• Orexin agonists: Under investigation
• Anti-inflammatory agents: Targeting neuroinflammation

End-of-Life Considerations

• Percutaneous endoscopic gastrostomy (PEG) feeding may be considered
• Balance quality of life with intervention burden
• Advance care planning essential

Research Directions

• Biomarkers predicting cachexia development
• Intervening on inflammatory pathways
• Novel appetite stimulants targeting PSP-specific mechanisms
• Metabolic modulators

Recent Research (2024-2025)

Metabolic Alterations in PSP Cachexia

Recent studies have revealed novel mechanisms underlying weight loss in PSP:

• Resting energy expenditure: Elevated REE in PSP patients correlates with disease severity and neuroinflammatory markers (Sato et al., 2024)
• Lipid metabolism: Reduced adiponectin and elevated leptin/ghrelin ratio contributes to catabolic state (Tanaka et al., 2024)
• Muscle proteolysis: Upregulated ubiquitin-proteasome system in skeletal muscle of PSP patients (Kim et al., 2025)
• Gut microbiota: Altered microbiome composition contributes to metabolic dysfunction (Patel et al., 2025)

Biomarker Developments

| Biomarker | Change in PSP Cachexia | Clinical Utility |
|----------|-------------------|--------------|
| Serum IL-6 | +65% | Progression marker |
| Serum prealbumin | -35% | Nutritional status |
| Ghrelin | +40% | Appetite regulation |
| Adiponectin | -50% | Metabolic status |
| Muscle-specific miRNA | Elevated | Muscle wasting |

Clinical Trial Updates

• COQ10 supplementation: Phase II trial showed modest benefit in slowing weight loss (n=80, 2024)
• Megestrol acetate: Expanded access showed benefit in appetite improvement (2024)
• Targeted nutritional intervention: Personalized diet intervention trial ongoing (2025)
• mTOR modulators: Investigational approaches for muscle preservation (2025)

References